People: Celgene Corporation (CELG.O)

CELG.O on Nasdaq

55.50USD
9 Feb 2010
Price Change (% chg)

$0.73 (+1.33%)
Prev Close
$55.50
Open
--
Day's High
$56.33
Day's Low
$55.01
Volume
2,926,769
Avg. Vol
3,468,169
52-wk High
$59.67
52-wk Low
$36.90

view people for:

Summary

Name Age Since Current Position
Barer, Sol 62 2007 Chairman of the Board, Chief Executive Officer
Hugin, Robert 54 2006 President, Chief Operating Officer, Director
Gryska, David 53 2006 Chief Financial Officer, Senior Vice President
Brouwer, Aart 69 2009 Chairman, International
Burton, Graham 58 2003 SVP - Global Regulatory Affairs, Pharmacovigilance and Corporate Quality & Compliance
Casey, Michael 63 2007 Lead Independent Director
Hayes, Arthur 75 1995 Director
Kaplan, Gilla 62 1998 Director
Robb, Walter 80 1992 Director
Drake, Rodman 66 2006 Director
Loughlin, James 66 2007 Director
Mario, Ernest 70 2007 Director
Cox, Carrie 52 2009 Director
» Insider Trading

Biographies

Name Description
Barer, Sol Dr. Sol J. Barer has been Chief Executive Officer of Celgene Corporation since May 1, 2006 and Chairman since January 1, 2007. He was appointed President in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors. He previously served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from 1991 to 1994, and the Vice President, Technology, from 1987 to 1991. Dr. Barer is on the Board of Trustees of Rutgers University, Board of Directors of PhRMA, serves on the Board of Trustees of the Biotechnology Council of New Jersey and is on the Board of the Brooklyn College Foundation. He has previously served as a Commissioner of the NJ Commission on Science and Technology. Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University. Dr. Barer is also a director of Amicus Therapeutics and serves on the Board of Trustees of BioNJ and the Board of the Brooklyn College Foundation. Dr. Barer previously served as Commissioner of the New Jersey Commission on Science and Technology.
Hugin, Robert Robert J. Hugin has served as the Chief Operating Officer and President of Celgene Corp since May 1, 2006. He served as the Senior Vice President and Chief Financial Officer from June 1999 until May 1, 2006. Mr. Hugin has served as one of the directors of the Company since December 2001. Previously, Mr. Hugin had been a Managing Director at J.P. Morgan & Co. Inc., which he joined in 1985. Mr. Hugin received an A.B. degree from Princeton University and an M.B.A. from the University of Virginia. Mr. Hugin is also a director of The Medicines Company, Atlantic Health System, Inc., a non-profit health care system, and Family Promise, a national nonprofit network assisting homeless families.
Gryska, David David W. Gryska joined the company as Senior Vice President and Chief Financial Officer effective of Celgene Corp December 6, 2006. Mr. Gryska most recently has held several Board positions of biotechnology companies and is currently on the Board of SeattleGenetics. Previously, Mr. Gryska served at Scios, Inc., a biopharmaceutical company, as Senior Vice President and Chief Financial Officer from November 2000 to October 2004, and as Vice President of Finance and Chief Financial Officer from December 1998 to November 2000. Mr. Gryska served as a partner at Ernst & Young LLP, an accounting firm, for eleven years where he focused on technology industries, with an emphasis on biotechnology and healthcare companies. Mr. Gryska holds a B.A. in accounting and finance from Loyola University and an M.B.A. from Golden Gate University.
Brouwer, Aart Aart Brouwer is Chairman, International of Celgene Corp effective January 1, 2009. He had served as the President International since November 2, 2005. Mr. Brouwer joined the company as President of Celgene International in November 2005. Since then, his responsibilities have increased to the extent where he has become one of the executive officers, even though his title remains the same. Prior to Celgene, Mr. Brouwer served as a director of IsoTis S.A., a publicly owned medical device company specializing in orthobiologics, since 2002 and director of IsoTis, Inc. since 2006. Mr. Brouwer has held a range of senior marketing and management functions in the global pharmaceutical and biotech industries.
Burton, Graham Dr. Graham Burton has served as the Senior Vice President - Global Regulatory Affairs, Pharmacovigilance and Corporate Quality & Compliance from July 2003. Since then, his responsibilities have increased to the extent where he has become one of the executive officers, even though his title remains the same. Previously, Dr. Burton had been Senior Vice President Global Regulatory Affairs and Quality Assurance at Johnson & Johnson Pharmaceutical Research & Development, LLC from 1997 to 2003.
Casey, Michael Michael D. Casey has served as one of the directors of Celgene Corp since August 2002, is Chairman of the Nominating Committee, and serves on the Executive Committee as of December 2006 and, since April 19, 2006, the Management Compensation and Development Committee (referred to as the Compensation Committee), of the Board of Directors. He became the lead independent director on June 12, 2007. Mr. Casey was a member of the Audit Committee from August 2002 through December 2006. From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products division of Schein. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a director of Allos Therapeutics, Inc., Durect Corp. and AVI BioPharma.
Hayes, Arthur Arthur Hull Hayes, Jr., M.D. has served as one of the directors of Celgene Corp since 1995 and is a member of the Audit Committee of the Board of Directors. Dr. Hayes was President and Chief Operating Officer of MediScience Associates, a consulting organization that works with pharmaceutical firms, biomedical companies and foreign governments, from July 1991 through December 2005, and clinical professor of medicine and pharmacology at the Pennsylvania State University College of Medicine, from 1981 to 2004. From 1986 to 1990, Dr. Hayes was President and Chief Executive Officer of E.M. Pharmaceuticals, a unit of E. Merck AG, and from 1981 to 1983 was Commissioner of the U.S. Food and Drug Administration. Dr. Hayes is also a director of Myriad Genetics, Inc., QuantRx Biomedical Corporation and Tapestry, Inc.
Kaplan, Gilla Gilla Kaplan, Ph.D. has served as one of the directors since April 1998 and is a member of the Audit Committee of the Board of Directors. Dr. Kaplan is head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark, New Jersey, where she was appointed full Member in 2002. Dr. Kaplan also was appointed, in 2005, Professor of Medicine at the University of Medicine and Dentistry of New Jersey. Previously, Dr. Kaplan was an immunologist in the Laboratory at Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor.
Robb, Walter Walter L. Robb, Ph.D. has served as one of the directors of Celgene Corp since 1992 and is the Chairman of the Audit Committee of the Board of Directors. He has been a private consultant and President of Vantage Management Inc., a consulting and investor services company, since January 1993. Dr. Robb was Senior Vice President for Corporate Research and Development of General Electric Company, and a member of its Corporate Executive Council from 1986 to December 1992. Dr. Robb is Chairman of the Board of Directors of Capital District Sports. He is also a director of Mechanical Technology, Inc., a public company, and several private companies.
Drake, Rodman Rodman L. Drake has served as one of the directors of Celgene Corp since April 19, 2006 and as a member of the Nominating Committee and the Compensation Committee of the Board of Directors. Since January 2002, Mr. Drake has been Managing Director of Baringo Capital LLC, a private equity group he co-founded. From November 1997 to January 2002, Mr. Drake was president of Continuation Investments Group Inc., a private equity firm. Prior to that, Mr. Drake was co-chairman of the KMR Power Company and Chief Executive Officer and Managing Director of Cresap McCormick and Paget, a management consulting firm, and served as President of the Mandrake Group, a consulting firm specializing in strategy and organizational design. He is a member of the boards of directors of Student Loan Corporation, Jackson Hewitt, Apex Silver Corporation, Crystal River Capital and the Animal Medical Center of New York. He is the Chairman of the Hyperion Brookfield Funds and a Trustee of the Columbia Atlantic Funds. Mr. Drake received his B.A. degree from Yale University and his M.B.A. from Harvard Business School.
Loughlin, James James J. Loughlin has served as one of the directors of Celgene Corp since January 8, 2007 and is Chairman of the Audit Committee (since June 2008) and a member of the Compensation Committee (since June 2008) of our Board of Directors. Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG, including a five-year term as member of the Board of Directors of KPMG LLP. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees.
Mario, Ernest Ernest Mario, Ph.D. was appointed by a majority of the Board of Directors of Celgene Corp on August 22, 2007 and serves on the Nominating Committee of the Board of Directors. Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc. and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario has been a Director of Boston Scientific since October 2001 and is currently Chairman of Pharmaceutical Product Development. From 2003 to 2007, he was Chairman and Chief Executive of Reliant Pharmaceuticals. Dr. Mario was recently appointed the Chief Executive Officer of Capnia, Inc. A former Trustee of Duke University, he serves on the Board of the Duke University Health System. He is a past Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to the pharmacy schools at the University of Maryland, the University of Rhode Island and The Ernest Mario School of Pharmacy at Rutgers University. Dr. Mario is the recipient of the 2007 Remington Honor Medal, which is the highest recognition given by the American Pharmacists Association.
Cox, Carrie Ms. Carrie S. Cox has been appointed as Director of Celgene Corporation. She has served as executive vice president and president of Schering-Plough's Global Pharmaceutical Business. Before joining Schering-Plough, Ms. Cox served as executive vice president and president of Pharmacia Corporation's Global Prescription Business. Ms. Cox is a member of the Board of Directors of Texas Instruments and served on their audit and compensation committees, as well as recently being appointed to the Board of Directors of Cardinal Health. She is also a member of the Harvard School of Public Health's Health Policy and Management Executive Council and a member of the Board of Overseers of the University of Pennsylvania Museum of Archaeology and Anthropology.

Basic Compensation

Name Fiscal Year Total
Barer, Sol 8,525,090
Hugin, Robert 5,158,400
Gryska, David 2,138,500
Brouwer, Aart 1,705,110
Burton, Graham 3,070,900
Casey, Michael --
Hayes, Arthur --
Kaplan, Gilla --
Robb, Walter --
Drake, Rodman --
Loughlin, James --
Mario, Ernest --
Cox, Carrie --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Barer, Sol 4,933,049 128,659,904
Hugin, Robert 4,079,153 132,592,104
Gryska, David 23,264 160,987
Brouwer, Aart 0 0
Burton, Graham 135,571 7,266,340
Casey, Michael 0 0
Hayes, Arthur 0 0
Kaplan, Gilla 0 0
Robb, Walter 0 0
Drake, Rodman 0 0
Loughlin, James 0 0
Mario, Ernest 0 0
Cox, Carrie 0 0

Insider Trading

Name Shares Traded Price
KAPLAN GILLA 20,000 $58.04
KAPLAN GILLA 20,000 $14.92
BURTON GRAHAM H 39,639 $52.23
HUGIN ROBERT J 105,000 $53.62
HUGIN ROBERT J 105,000 $6.45
HUGIN ROBERT J 315,000 $6.45
HUGIN ROBERT J 315,000 $53.52
BARER SOL J 600,000 $6.45
BARER SOL J 600,000 $52.12
KAPLAN GILLA 40,000 $51.50
KAPLAN GILLA 40,000 $14.92
ROBB WALTER L 7,500 $28.50
BURTON GRAHAM H 1,000 $7.78
BURTON GRAHAM H 11,408 $14.16
BURTON GRAHAM H 11,248 $13.09
ROBB WALTER L 7,500 $19.86
ROBB WALTER L 15,000 $41.59
ROBB WALTER L 7,500 $16.94
LOUGHLIN JAMES J 600 $39.57
KAPLAN GILLA 20,000 $7.70
ROBB WALTER L 7,500 $14.19
ROBB WALTER L 15,000 $10.97
ROBB WALTER L 15,000 $14.50
ROBB WALTER L 15,000 $13.68
DRAKE RODMAN L 795 $49.75
» Full list on Insider Trading
view people for: